Press Releases

Chai Discovery, which builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, today announced a breakthrough in the de novo design of antibodies. The company’s latest model, Chai-2, demonstrates a remarkable antibody design hit rate close to 20%. Prompted with just the target and epitope, Chai-2 successfully designs all complementarity-determining regions (CDRs) entirely from scratch—a breakthrough in a field where tradition

HanchorBio In, a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai Henlius Biotech, Inc. (hereafter "Henlius"). The deal grants Henlius exclusive development and commercialization rights to HCB101 across Greater China (including Mainland China, Hong Kong, and Macau), key Southeast Asian countries, as well as all countries in the Middle Ea

Aenova, a leading global contract development and manufacturing organization (CDMO), is investing in a new cold chain warehouse at its sterile site in Latina, Italy. The cutting-edge facility marks a significant milestone in Aenova’s commitment to providing end-to-end integrated supply chain solutions for biologics and other temperature-sensitive pharmaceutical products. The new warehouse, adjacent and fully connected to the existing facility, represents a strategic exp

Moderna, Inc. today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study popul

Hansa Biopharma AB, “Hansa, announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase, at the 2025 International Transplant Congress of the European Society for Organ Transplantation (ESOT), taking place in London, June 29 – July 2. Massimo Mangiola, PhD, NYU Langone Transplan

UCB, a global biopharmaceutical company, today announced that the phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 Deficiency Disorder (CDD) met its primary and key secondary endpoints.1 The study is a randomized, double-blind, placebo-controlled, fixed-dose, multi-center study examining the efficacy, safety, and pharmacokinetics of adjunctive fenfluramine treatment in 87 children and adults aged 1 – 35, with a CDD diagnosis and uncontrolled seizur

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of large B cell lymphoma (LBCL) and other lymphomas and Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of multiple myeloma. These label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) pr

LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality and cost-competitive large-scale manufacturing capacities. The collaboration leverages LTS's global expertise in technology transfer, scale-up, and manufacturing, providing Nualtis with resources to scale th

 Valneva SE, a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO® and cholera/ETEC1 vaccine D

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and SteinCares, a leading specialty healthcare company in Latin America, today announced the signing of a new agreement to commercialize a proposed biosimilar of dupilumab across Latin America. This is the fourth product that the two companies agree to collaborate and strengthens their shared commitment to improving access to high-quality, cost-effective thera